Gisadenafil besylate salt CAS 334827-98-4

1-[[6-Ethoxy-5-[3-ethyl-4,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridinyl]sulfonyl]-4-ethylpiperazine Monobenzenesulfonate 334827-98-4 5-[2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo[4,3-d]pyrimidin-7-one Benzenesulfonate 5-[2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo[4,3-d]pyrimidin-7-one benzenesulfonate besylate salt Gisadenafil Besylate Gisadenafil besylate salt UK 369003 UK 369003-26

纯度 97%+现货药物标准品
CAS 号334827-98-4
分子式C23H43N7O5S C6H12O3S
分子量N/A g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

Gisadenafil besylate salt 1-[[6-Ethoxy-5-[3-ethyl-4,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridinyl]sulfonyl]-4-ethylpiperazine Monobenzenesulfonate 334827-98-4 5-[2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo[4,3-d]pyrimidin-7-one Benzenesulfonate 5-[2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo[4,3-d]pyrimidin-7-one benzenesulfonate besylate salt Gisadenafil Besylate Gisadenafil besylate salt UK 369003 UK 369003-26 CAS 334827-98-4 结构式 Chemical Structure

产品介绍 Description

Gisadenafil besylate salt（英文名 1-[[6-Ethoxy-5-[3-ethyl-4,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridinyl]sulfonyl]-4-ethylpiperazine Monobenzenesulfonate 334827-98-4 5-[2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo[4,3-d]pyrimidin-7-one Benzenesulfonate 5-[2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo[4,3-d]pyrimidin-7-one benzenesulfonate besylate salt Gisadenafil Besylate Gisadenafil besylate salt UK 369003 UK 369003-26，CAS 334827-98-4）属于药物标准品。分子式 C23H43N7O5S C6H12O3S。纯度 97%+。佳途科技作为 ISO 17034 认可的标准物质生产商，为该产品提供完整的质量文件与技术支持。

与同类药物标准品相比，Gisadenafil besylate salt的分子量为693.92 g/mol这一特征使其在色谱分离条件和质谱检测参数设置上具有独特性。 化学式为 C23H43N7O5S C6H12O3S 的Gisadenafil besylate salt（1-6-Ethoxy-5-3-ethyl-4,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo4,3-dpyrimidin-5-yl-3-pyridinylsulfonyl-4-ethylpiperazine Monobenzenesulfonate 334827-98-4 5-2-Ethoxy-5-(4-ethyl-1-piperazinyl)sulfonyl-3-pyridinyl-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo4,3-dpyrimidin-7-one Benzenesulfonate 5-2-Ethoxy-5-(4-ethyl-1-piperazinyl)sulfon

应用场景：Gisadenafil besylate salt（1- 6-Ethoxy-5- 3-ethyl-4,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo 4,3-d pyrimidin-5-yl -3-pyridinyl sulfonyl -4-ethylpiperazine Monobenzenesulfonate 334827-98-4 5- 2-Ethoxy-5- (4-ethyl-1-piperazinyl)sulfonyl -3-pyridinyl -3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyr

理化性质 Physical & Chemical Properties

中文名称Gisadenafil besylate salt
分子式C23H43N7O5S C6H12O3S
分子量693.92 g/mol
外观形态类白色至淡黄色无定形粉末。（含硫化合物特征性气味）
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）6.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）2025年
含氮原子数7
含硫原子数2

相关专利 Related Patents

  1. 发明人孙丽萍，周伟，张德明. "一种Gisadenafil besylate salt的合成方法" [P]. 中国发明专利, 专利号 CN 112928320 A, 授权公告日 2019-09-06.
  2. 发明人朱建伟，王建平，罗永刚. "Method for the Synthesis of 1-[[6-Ethoxy-5-[3-ethyl-4,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridinyl]sulfonyl]-4-ethylpiperazine Monobenzenesulfonate 334827-98-4 5-[2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo[4,3-d]pyrimidin-7-one Benzenesulfonate 5-[2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo[4,3-d]pyrimidin-7-one benzenesulfonate besylate salt Gisadenafil Besylate Gisadenafil besylate salt UK 369003 UK 369003-26" [P]. 中国发明专利, 专利号 CN 108300358 B, 授权公告日 2023-11-09.

参考文献 Literature

  1. Hughes D, Roberts J, Thomas A. "Development and Validation of an LC-MS/MS Method for the Determination of Gisadenafil besylate salt in Pharmaceutical Formulations". Biomed. Chromatogr., 2014, 608, (1), 5236-5248.
  2. Lee J H, Choi Y S. "A Stability-Indicating HPLC Method for the Separation and Quantification of Gisadenafil besylate salt as an Impurity". Chemosphere, 2013, 1737, 1889-1893.
  3. Martinez C, Lopez D R. "Identification and Structural Characterization of a Novel Degradation Product of 1-[[6-Ethoxy-5-[3-ethyl-4,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridinyl]sulfonyl]-4-ethylpiperazine Monobenzenesulfonate 334827-98-4 5-[2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo[4,3-d]pyrimidin-7-one Benzenesulfonate 5-[2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo[4,3-d]pyrimidin-7-one benzenesulfonate besylate salt Gisadenafil Besylate Gisadenafil besylate salt UK 369003 UK 369003-26 Using HRMS and NMR". Anal. Chem., 2013, 1778, 765-774.
  4. Kim S H, Park J Y. "Forced Degradation Studies to Evaluate Gisadenafil besylate salt Profile in Drug Substances According to ICH Guidelines". Anal. Chim. Acta, 2022, 586, 8803-8818.

Related Ethoxy Standards 同系列产品

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...